Medtech flat at Bristol-Myers
This article was originally published in Clinica
Medical device sales are failing to show much buoyancy at Bristol-Myers Squibb. In the first quarter, they fell 1% which, adjusted for unfavourable exchange rate moves, would have been a 2% increase. This follows a similar trend in 1996 when medical device sales declined 2% to $1,860 million (see Clinica No 741, p 11).
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.